« Zurück
Startseite /
Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP2-F6) - Purified No Carrier Protein - 100 µg

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP2-F6) - Purified No Carrier Protein - 100 µg

ArtNr	LEIN-LT7025-100ug
Hersteller	Leinco Technologies
Menge	100 ug
Quantity options	100 ug 500 ug
Kategorie	Antibodies ELISA Primary Antibodies Immunostaining
Typ	Antibody Monoclonal
Applikationen	ELISA
Clon	NP2-F6
Specific against	Virus, SARS-CoV-2
Host	Mouse
Purity	≥95% monomer by analytical SEC
NCBI	43740575
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Quality Tested by Leinco ELISA
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases\|Monoclonal Antibodies\|Recombinant Antibodies\|SARS-CoV-2
Manufacturer - Targets	SARS-CoV-2 Nucleocapsid (N)
Country of Origin	USA
Shipping Temperature	Ships Overnight on Blue Ice
Storage Conditions	This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Product Description	Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the Coronaviridae family, and its single-stranded, positive-sense RNA genome shares 79.6% identity with SARS-CoV1. The spike (S), envelope (E), membrane (M), and nucleocapsid proteins (N) are four essential structural proteins of SARS-CoV-22. The 46 kDa N protein is highly conserved and shares 90% homology with SARS-CoV3. Similar to SARS-CoV, SARS-CoV-2 has an N-terminal (NTD) and C-terminal domain (CTD), linked by a linker region. The NTD binds to RNA, while the CTD self-oligomerizes4, 5, aiding viral genome packaging into a helical ribonucleoprotein complex6. The N protein also participates in viral transcription, replication, and modulation of cell signaling pathways7, 8. Some vaccine and diagnostic assays9 have focused on the N protein as it is highly expressed during infection and activates antibodies3, 10 and memory T cells11, 12, found in convalescent sera. The N-protein also evades the innate immune system by inhibiting RNAi13, identifying it as a potential therapeutic target.
Background	Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the Coronaviridae family, and its single-stranded, positive-sense RNA genome shares 79.6% identity with SARS-CoV¹. The spike (S), envelope (E), membrane (M), and nucleocapsid proteins (N) are four essential structural proteins of SARS-CoV-2². The 46 kDa N protein is highly conserved and shares 90% homology with SARS-CoV³. Similar to SARS-CoV, SARS-CoV-2 has an N-terminal (NTD) and C-terminal domain (CTD), linked by a linker region. The NTD binds to RNA, while the CTD self-oligomerizes^{4, 5}, aiding viral genome packaging into a helical ribonucleoprotein complex⁶. The N protein also participates in viral transcription, replication, and modulation of cell signaling pathways^{7, 8}. Some vaccine and diagnostic assays⁹ have focused on the N protein as it is highly expressed during infection and activates antibodies^{3, 10} and memory T cells^{11, 12}, found in convalescent sera. The N-protein also evades the innate immune system by inhibiting RNAi¹³, identifying it as a potential therapeutic target.
PubMed	SARS-CoV-2 Nucleocapsid (N)
Manufacturer - Research Area	COVID-19, Infectious Disease, Seasonal and Respiratory Infections, Viral, IVD Raw Material
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	Anti-SARS-CoV-2 Nucleocapsid, clone NP2-F6, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein.
RRID	AB_2892939
Concentration	≥1.0 mg/ml
Formulation	This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Antigen Distribution	The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Immunogen	SARS-CoV-2 Nucleocapsid (N) Protein
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, Monoclonal Antibody, COVID-19

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-LT7025-100ug-safety-datasheet.pdf